HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Paolo Bironzo et al.|Journal of Clinical Oncology|2023Cited by 224
Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Haniel A. Araújo et al.|Cancer Discovery|2023Cited by 181
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancerAarif Siddiqui, Paolo Ceppi, Paradesi Naidu Gollavilli et al.|British Journal of Cancer|2020Cited by 49
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancerAarif Siddiqui, Paolo Ceppi, Paradesi Naidu Gollavilli et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 3
OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01Helena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Thoracic Oncology|2023Cited by 1